Q3 2022 13F Holders as of 30 Sep 2022
-
Type / Class
-
Equity / COM
-
Number of holders
-
102
-
Total 13F shares, excl. options
-
29,944,096
-
Shares change
-
-22,602
-
Total reported value, excl. options
-
$383,463,101
-
Value change
-
+$7,943,628
-
Put/Call ratio
-
49%
-
Number of buys
-
58
-
Number of sells
-
-35
-
Price
-
$12.84
Significant Holders of Kiniksa Pharmaceuticals Intern - COM (KNSA) as of Q3 2022
122 filings reported holding KNSA - Kiniksa Pharmaceuticals Intern - COM as of Q3 2022.
Kiniksa Pharmaceuticals Intern - COM (KNSA) has 102 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 29,944,096 shares
.
Largest 10 shareholders include BlackRock Inc. (3,628,460 shares), VANGUARD GROUP INC (3,079,192 shares), PICTET ASSET MANAGEMENT SA (3,037,861 shares), HHLR ADVISORS, LTD. (2,920,023 shares), BAKER BROS. ADVISORS LP (2,799,577 shares), Rubric Capital Management LP (1,446,107 shares), Hudson Bay Capital Management LP (1,200,000 shares), MILLENNIUM MANAGEMENT LLC (943,199 shares), ArrowMark Colorado Holdings LLC (928,094 shares), and GOLDMAN SACHS GROUP INC (905,268 shares).
This table shows the top 102 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.